1 Incredible Reason to Buy Pfizer Stock (PFE) in November

Core Viewpoint - Pfizer is currently an attractive investment option primarily due to its high dividend yield of 7%, which surpasses the interest rates offered by high-yield bank savings accounts [2][5]. Dividend Performance - Historical data indicates that dividend-paying stocks have provided strong returns, with dividend growers and initiators averaging an annual total return of 10.24% from 1973 to 2024 [4]. - Pfizer has a history of raising its dividend annually for 16 years, contributing to its reputation as a solid dividend payer [9]. Stock Performance and Valuation - Pfizer's stock has declined over 35% in the past three years, contrasting with an 84% increase in the S&P 500 index during the same period [5]. - The company's current forward-looking price-to-earnings (P/E) ratio is 8, which is below its five-year average of 10, indicating a potentially attractive valuation for investors [8]. Business Dynamics - The decline in Pfizer's stock price is attributed to reduced demand for its COVID-19 vaccine and Paxlovid treatment, which had previously driven significant revenue growth [6]. - Pfizer is actively developing a pipeline of new drugs and has made acquisitions, such as the recent purchase of weight-loss drug developer Metsera, which may impact future dividend policies [6][7].